Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076003 | 1.00 | HTR2A (0.37) | HTR2AHTR2CHTR2BP2RX7L3MBTL1 | |
| SCHEMBL4076007 | 1.00 | HTR2A (0.37) | HTR2AHTR2CHTR2BP2RX7L3MBTL1 | |
| SCHEMBL4156479 | 1.00 | HTR2A (0.37) | HTR2AHTR2CHTR2BP2RX7L3MBTL1 | |
| SCHEMBL3062528 | 0.80 | L3MBTL1 (0.44) | HTR2AHTR2CHTR2BL3MBTL1CA1 | |
| SCHEMBL3956423 | 0.73 | KDM1A (0.51) | HTR2CL3MBTL1TRPM8KDM1A | |
| SCHEMBL3956419 | 0.73 | KDM1A (0.51) | HTR2CL3MBTL1TRPM8KDM1A | |
| SCHEMBL4064540 | 0.73 | KDM1A (0.51) | HTR2CL3MBTL1TRPM8KDM1A | |
| SCHEMBL3956658 | 0.71 | TRPM8 (0.41) | HTR2AHTR2CHTR2BSLC40A1TRPM8 | |
| SCHEMBL3962688 | 0.70 | L3MBTL1 (0.53) | HTR2CL3MBTL1TRPM8KDM1A | |
| SCHEMBL3957475 | 0.67 | L3MBTL1 (0.49) | HTR2AHTR2CHTR2BL3MBTL1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HTR2A 84/4885HTR2C 99/4885HTR2B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.